NVUS 2018 Annual Report

NOVUS THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share data)

December 31,

2018

2017

ASSETS

Current assets:

Cash and cash equivalents

$

12,972 $

17,233

Restricted cash

Ͷ

70

Prepaid expenses and other current assets

1,304 14,276

1,697 19,000

Total current assets

Property and equipment, net

14

25

Goodwill

1,867

1,867

Other assets Total assets

Ͷ

869

$

17,026 $

20,892

LIABILITIES AND STOCKHOLDERS ͛ EQUITY

Accounts payable Accrued severance

$

689 $

418 668 354

Ͷ

Accrued expenses and other liabilities

1,845 2,534

Total liabilities

1,440

Commitments and contingencies (Note 6) Stockholders ͛ equity: Preferred stock, $0.001 par value, 5,000,000 shares authorized and none issued and outstanding at December 31, 2018 and 2017 Common stock, $0.001 par value, 200,000,000 shares authorized at December 31, 2018 and 2017; 9,422,143 and 7,110,414 shares issued and outstanding at December 31, 2018 and 2017, respectively

Ͷ

Ͷ

9

7

Additional paid-in capital Accumulated deficit Total stockholders ͛ equity

56,054 (41,571)

46,951 (27,506)

14,492

19,452 20,892

Total liabilities and stockholders ͛ equity

$

17,026 $

See accompanying notes to consolidated financial statements.

F-3